Compass Therapeutics: D. Boral Capital maintains Buy, PT raised to $32.

Compass Therapeutics: D. Boral Capital maintains Buy, PT raised to $32.

D. Boral Capital has maintained its Buy rating on Compass Therapeutics (NASDAQ:CMPX) while raising its price target to $32, according to a recent analyst report. The update comes on the heels of positive clinical data and pipeline advancements from the biotech company.

Compass Therapeutics reported encouraging initial clinical data from its Phase 1 study of CTX-8371, a PD1 x PD-L1 bispecific antibody, showing two confirmed monotherapy responses among 12 treated patients, with some experiencing deep tumor reductions of up to 100% in target lesions [1]. Additionally, the company announced a revised timeline for the final PFS & OS analysis of its COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer, now expected in the first quarter of 2026 instead of the fourth quarter of 2025 [1].

Despite a net loss of $19.9 million and earnings per share (EPS) of -$0.14 in the second quarter of 2025, which was slightly wider than the anticipated loss of -$0.12, the company ended the quarter with approximately $101 million in cash and equivalents, which management expects will support operations into 2027 [2]. Raymond James maintained its Outperform rating for Compass Therapeutics, setting a price target of $9.00 [2].

Guggenheim, another analyst firm, cited the addition of probability-of-success-adjusted value for CTX-8371 and increased confidence in tovecimig as key factors behind its price target increase to $12.00 [1]. The stock has shown remarkable momentum, delivering a 195% return over the past year and 130% year-to-date [1].

These developments reflect ongoing investor interest and analyst confidence in Compass Therapeutics, despite the earnings miss. The company remains on track for fourth-quarter 2025 IND submission of CTX-10726, its PD-1 x VEGF-A bispecific antibody, and presented preclinical data suggesting superiority over competitor Akeso’s ivonescimab [1].

References:
[1] https://www.investing.com/news/analyst-ratings/guggenheim-raises-compass-therapeutics-stock-price-target-on-promising-clinical-data-93CH-4184909
[2] https://ca.investing.com/news/analyst-ratings/guggenheim-raises-compass-therapeutics-stock-price-target-on-promising-clinical-data-93CH-4151920